Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-6345
- Development stage
- Unknown
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MT-6345 is a small molecule drug that was developed by Mitsubishi Tanabe Pharma for the treatment of nervous system diseases, with a primary focus on binge eating disorder (BED). The drug entered Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy subjects. However, development was discontinued after Phase 1. The precise mechanism of action for MT-6345 has not been disclosed or remains unknown[1][2][3][4][5].
Beyond the preview
Go deeper on MT-6345.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-6345.